This inventor holds 7 USPTO granted patents and 11 published patent applications. Top assignees: Alnylam Pharmaceuticals, Inc., Novartis Ag. Active years: 2021-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Cambridge, MA (US) (2021)
- Weston, MA (US) (2024)
Company Filing History:
Years Active: 2021-2026
Title: Mark Keating: Innovator in RNAi Therapeutics
Introduction
Mark Keating is a prominent inventor based in Weston, MA, known for his significant contributions to the field of RNA interference (RNAi) therapeutics. With a total of five patents to his name, he has made strides in developing innovative solutions for various medical conditions.
Latest Patents
Among his latest patents is the invention titled "Complement component C3 iRNA compositions and methods of use thereof." This invention focuses on RNAi agents, specifically double-stranded RNA (dsRNA) agents, that target the complement component C3 gene. The methods described in this patent aim to inhibit the expression of the C3 gene and provide therapeutic options for treating C3-associated disorders, including cold agglutinin disease, warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria, among others.
Another notable patent is "Coagulation factor V (F5) iRNA compositions and methods of use thereof." This invention also relates to RNAi agents targeting the Coagulation Factor V gene. The methods outlined in this patent are designed to inhibit the expression of the F5 gene and offer potential treatments for diseases associated with thrombosis.
Career Highlights
Mark Keating has worked with leading companies in the pharmaceutical industry, including Alnylam Pharmaceuticals, Inc. and Novartis AG. His experience in these organizations has contributed to his expertise in developing RNAi-based therapies.
Collaborations
Throughout his career, Mark has collaborated with notable professionals in the field, including James D. McIninch and Mark K. Schlegel. These collaborations have further enhanced his research and development efforts.
Conclusion
Mark Keating's innovative work in RNAi therapeutics has the potential to transform treatment options for various medical conditions. His patents reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile